FDA approves Roche, PTC drug for spinal muscular atrophy August 10, 2020 Auto Bot BioPharma, biopharma nl, Evrysdi, New Jersey, PTC Therapeutics, Risdiplam, Roche, spinal muscular atrophy 0 Analysts noted that Evrysdi would be priced significantly lower than Biogen’s Spinraza or Novartis’ Zolgensma. While this will provide a market advantage, it would also yield lower per-patient revenues.